Enterprise Value
8.284B
Cash
894.6M
Avg Qtr Burn
N/A
Short % of Float
3.33%
Insider Ownership
1.06%
Institutional Own.
95.26%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INGREZZA (valbenazine) Details Huntington's disease, Dyskinesia | Approved Quarterly sales | |
Valbenazine Details Huntington's disease | PDUFA Approval decision | |
Valbenazine Details Dyskinesia due to Cerebral Palsy | Phase 3 Data readout | |
Crinecerfont Details Congenital adrenal hyperplasia | Phase 3 Data readout | |
Valbenazine Details Psychiatric disorder, Schizophrenia | Phase 2 Data readout | |
NBI-1065846 Details Major depressive disorder | Phase 2 Data readout | |
NBI-921352 Details Focal Onset Seizures | Phase 2 Data readout |